Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Shy-Drager Syndrome

• PET Imaging Evaluation of [11C]SY08
• A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
• Biomarker Study of ATH434 in Participants With MSA
• Biomarker Study of ATH434 in Participants With MSA
• Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- to Moderate Stage MSA
• Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
• Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)
• Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
• A Study of TAK-341 in Treatment of Multiple System Atrophy
• Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
• Study of ATH434 in Participants With Multiple System Atrophy
• A Study of Lu AF82422 in Participants With Multiple System Atrophy
• Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
• Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
• Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients
• Exenatide Once-weekly as a Treatment for Multiple System Atrophy
• [18F]F-DOPA Imaging in Patients With Autonomic Failure
• A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
• Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB101 Administered to Adults With Multiple System Atrophy
• Rituximab for Multiple System Atrphy
• Study of BHV-3241 in Subjects With Multiple System Atrophy
• Trial of Parkinson's And Zoledronic Acid
• Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy
• Safinamide for Multiple System Atrophy (MSA)
• Clinical Laboratory Evaluation of Chronic Autonomic Failure
• A Futility Trial of Sirolimus in Multiple System Atrophy
• Automated Abdominal Binder for Orthostatic Hypotension
• Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism
• Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial
• Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
• Norepinephrine Transporter Blockade, Autonomic Failure
• Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic
• TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
• Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure
• Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
• AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
• 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
• Water and Sudafed in Autonomic Failure
• Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA
• Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.
• Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach
• A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
• Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy
• Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure
• Study of Rifampicin in Multiple System Atrophy
• Fluoxetine in Multiple System Atrophy Patients
• Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study
• The Role of Endothelin in the Supine Hypertension of Autonomic Failure
• Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study
• Nebivolol in the Supine Hypertension of Autonomic Failure
• Lithium in Multiple System Atrophy
• Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
• Botulinum A Toxin in Patients With Parkinson's Disease
• Fipamezole in Neurogenic Orthostatic Hypotension
• Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
• Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
• Augmenting Effects of L-DOPS With Carbidopa and Entacapone
• Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
• The Autonomic Nervous System and Obesity
• Study About Efficacy and Safety to Treat Multi-System-Atrophy
• Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
• Droxidopa in Treating Patients With Neurogenic Hypotension